Control or Mitigation of the Effects of Chronic Neuroinflammation
Tuesday, May 3, 2022
Chronic inflammation in the brain is now recognized as a contributor to many neurodegenerative diseases, ranging from Parkinson’s disease to multiple sclerosis to Alzheimer’s disease. Are solutions to these historically intractable neurological diseases imminent or several years away? Are market-making platforms identifiable for neurological diseases? Are there novel genetic targets that can be explored? What are the prospects for cell therapies?
- Moderator:
-
- Ole Isacson, MD, PhD
-
- Director, Neuroregeneration Research Institute, McLean
- Professor of Neurology & Neuroscience, HMS
- Panelists:
-
- Colin Hill
-
- CEO, GNS Healthcare
- Spyros Papapetropoulos, MD, PhD
-
- CMO, Vigil Neuroscience
- Richard Ransohoff, MD
-
- CMO, Abata Therapeutics
- Venture Partner, Third Rock Ventures
- Beth Stevens, PhD
-
- HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children's Hospital
- Associate Professor of Neurology, HMS
- Rudolph Tanzi, PhD
-
- Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH
- Joseph P. and Rose F. Kennedy Professor of Neurology, HMS